Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction ended on 30.03.24 with a price of €902.40. The prediction closed with a disappointing performance of 19.37%. Bank_of_America_Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc., but this time predicts that Regeneron Pharmaceuticals Inc. is a Buy. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.600% | -0.600% | 40.335% | -5.020% |
| iShares Core DAX® | -0,05 % | 5,96 % | 7,40 % | 65,85 % |
| iShares Nasdaq 100 | 0,92 % | 3,69 % | 28,14 % | 93,30 % |
| iShares Nikkei 225® | 3,01 % | 6,64 % | 48,89 % | 89,08 % |
| iShares S&P 500 | -0,36 % | 2,75 % | 22,53 % | 71,94 % |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
07.01.26
07.01.27
10:49
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
17.04.25
17.04.26
18.04.26
Regeneron Pharmaceuticals Inc.
12.04.24
12.04.25
13.04.25

